Pharmacogenomics-guided treatment versus conventional treatment in patients with Schizophrenia: Evaluation of medication adherence and switching rate.

IF 2.7 3区医学 Q3 PHARMACOLOGY & PHARMACY

European Journal of Clinical Pharmacology Pub Date : 2025-08-01 Epub Date: 2025-06-06 DOI:10.1007/s00228-025-03858-y

Jiaqi Wang, Yuhang Yan, Liguang Duan, Binliang Tong, Xiaochuan Zhao, Shi Su, Mengqiang Zhao, Chaoli Chen, Yang Lun, Yueyao Luan, Qixuan Sun, Yuanyuan Zhao, Jing Yu, Xiaoying Geng, Jincheng Wang, Chunhua Zhou

{"title":"Pharmacogenomics-guided treatment versus conventional treatment in patients with Schizophrenia: Evaluation of medication adherence and switching rate.","authors":"Jiaqi Wang, Yuhang Yan, Liguang Duan, Binliang Tong, Xiaochuan Zhao, Shi Su, Mengqiang Zhao, Chaoli Chen, Yang Lun, Yueyao Luan, Qixuan Sun, Yuanyuan Zhao, Jing Yu, Xiaoying Geng, Jincheng Wang, Chunhua Zhou","doi":"10.1007/s00228-025-03858-y","DOIUrl":null,"url":null,"abstract":"Purpose: The main objective of this study was to systematically evaluate the effectiveness of pharmacogenomics-guided treatment (PGxT) and treatment-as-usual (TAU) in schizophrenia management through two key indicators: medication adherence and antipsychotic switching rate.Methods: The study cohort comprised individuals with schizophrenia who were hospitalized between April 2022 and March 2024. The cohort was stratified into two groups: the PGxT and TAU. To address potential confounding between the groups, propensity score matching (PSM) was applied. The primary outcome measures were the proportions of patients with good medication adherence (≥ 80%) at three and six months after discharge and the antipsychotic switching rate.Results: Among the 420 patients in the PGxT and TAU groups obtained through propensity score matching, the proportions of patients with good medication adherence (≥ 80%) was 49.76% at three months and 33.10% at six months, with a significant difference between the follow-up periods (P < 0.001). During the three-month observation period, the proportion of patients demonstrating good adherence were significantly different (55.24% in PGxT group vs. 44.29% in TAU group; P = 0.032). The difference was also significant after six months (44.76% in PGxT group vs. 21.43% in TAU group; P < 0.001). Furthermore, the proportion of antipsychotic switching rate was lower in the PGxT group (25.71%) than in the TAU group (41.90%) (P < 0.001).Conclusion: This study observed an association between PGxT and higher adherence as well as lower medication switching rate in patients with schizophrenia, which suggests potential clinical utility of PGx testing.","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1187-1195"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-025-03858-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The main objective of this study was to systematically evaluate the effectiveness of pharmacogenomics-guided treatment (PGxT) and treatment-as-usual (TAU) in schizophrenia management through two key indicators: medication adherence and antipsychotic switching rate.

Methods: The study cohort comprised individuals with schizophrenia who were hospitalized between April 2022 and March 2024. The cohort was stratified into two groups: the PGxT and TAU. To address potential confounding between the groups, propensity score matching (PSM) was applied. The primary outcome measures were the proportions of patients with good medication adherence (≥ 80%) at three and six months after discharge and the antipsychotic switching rate.

Results: Among the 420 patients in the PGxT and TAU groups obtained through propensity score matching, the proportions of patients with good medication adherence (≥ 80%) was 49.76% at three months and 33.10% at six months, with a significant difference between the follow-up periods (P < 0.001). During the three-month observation period, the proportion of patients demonstrating good adherence were significantly different (55.24% in PGxT group vs. 44.29% in TAU group; P = 0.032). The difference was also significant after six months (44.76% in PGxT group vs. 21.43% in TAU group; P < 0.001). Furthermore, the proportion of antipsychotic switching rate was lower in the PGxT group (25.71%) than in the TAU group (41.90%) (P < 0.001).

Conclusion: This study observed an association between PGxT and higher adherence as well as lower medication switching rate in patients with schizophrenia, which suggests potential clinical utility of PGx testing.

查看原文本刊更多论文

精神分裂症患者的药物基因组学指导治疗与传统治疗：药物依从性和转换率的评估。

目的：本研究的主要目的是通过药物依从性和抗精神病药物转换率两个关键指标，系统评估药物基因组学指导治疗（PGxT）和常规治疗（TAU）在精神分裂症治疗中的有效性。方法：研究队列包括2022年4月至2024年3月住院的精神分裂症患者。该队列被分为两组：PGxT和TAU。为了解决组间潜在的混淆，应用倾向评分匹配（PSM）。主要结局指标是出院后3个月和6个月服药依从性良好（≥80%）的患者比例以及抗精神病药物转换率。结果：通过倾向评分匹配获得的420例PGxT组和TAU组患者中，3个月时药物依从性良好（≥80%）的患者比例为49.76%，6个月时为33.10%，随访期间差异显著(P)结论：本研究观察到PGxT与精神分裂症患者较高的依从性和较低的药物转换率之间存在相关性，提示PGx检测具有潜在的临床应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Pharmacology 医学-药学

CiteScore

5.40

自引率

3.40%

发文量

170

审稿时长

3-8 weeks

期刊介绍： The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.